Unlocking New Opportunities to Improve Brain Health

By advancing a pipeline of innovative drug candidates and digital medicine tools

MindMed Clinical Trials

We are researching and developing a broad range of compounds, with the goal of unlocking new pathways for patients to experience sustained mental healing.

CLINICAL TRIALS

PRE-DISCOVERY

DISCOVERY

PRE-CLINICAL

PHASE 1A

PHASE 2A

PHASE 2B

PHASE 3

MINDMED DEVELOP (Commercial Drug Development Programs)

Anxiety - Project Lucy

Anxiety - Project Lucy

PHASE 2A

18-MC

Opioid Withdrawal

Opioid Withdrawal

PHASE 2A

LSD Microdosing

Adult ADHD

Adult ADHD

PHASE 2A

MINDMED DISCOVER (R&D Collaborations)

University Hospital Basel

LSD Assisted Therapy

Cluster Headaches

Multiple Ongoing or Completed:
 on LSD, MDMA, DMT, Psilocybin

LSD Assisted Therapy

PHASE 2

Cluster Headaches

PHASE 2

Multiple Ongoing or Completed:
 on LSD, MDMA, DMT, Psilocybin

PHASE 1

Our Philosophy

Abstract swirl background
Abstract swirl background

Overcome

We focus on helping patients overcome rather than survive

We believe patients deserve better than to linger in symptom management forever. We help patients make breakthroughs that get them out of the symptom management cycle that’s all too commonplace in mental healthcare.

Community

We’re building a community with high standards of efficacy and compassion

Effective mental healthcare requires a coordinated effort from therapists, drug developers, and patients. We need shared data to drive insights and better treatment, so we’re working to build that community through partnerships and programs. We hold ourselves and our partners to the highest standards of efficacy and compassion so that we can progress the industry — and patient outcomes — faster.

Toolset

Next-Gen R&D

Developing best-in-class mental health care means more than clinical testing. In addition to conducting trials for the compounds we’re bringing to market, we’re also focused on next-gen research & development, comprehensive treatment programs and integrated toolsets that empower therapists to focus on what they do best.

People

We have the right people for the right reasons

Our interdisciplinary team of drug development veterans, savvy technologists, and mental health experts was purpose-built to tackle these challenges. With over a century of combined experience in product development and commercialization, we have the know-how and the heart to introduce a better approach to mental health.

Robert Barrow Portrait

Robert Barrow

Chief Executive Officer and Board Director

Miri Halperin Wernli, PhD Portrait

Miri Halperin Wernli, PhD

Executive President and Board Director

Cynthia Hu, JD Portrait

Cynthia Hu, JD

Chief Legal Officer & Corporate Secretary

Daniel Karlin, MD, MA Portrait

Daniel Karlin, MD, MA

Chief Medical Officer

Schond Greenway, MBA Portrait

Schond Greenway, MBA

Chief Financial Officer

Francois Lilienthal, MD, MBA Portrait

Francois Lilienthal, MD, MBA

Chief Commercial Officer

Robert Silva, PhD Portrait

Robert Silva, PhD

VP, Head of Development

Robert Malenka, MD, PhD Portrait

Robert Malenka, MD, PhD

Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University

Peter Bergethon, MD Portrait

Peter Bergethon, MD

Member, Scientific Advisory Board VP, Head of Quantitative & Clinical Technologies, Biogen, Inc.

Robert Dworkin, PhD Portrait

Robert Dworkin, PhD

Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry at University of Rochester

Maurizio Fava, MD Portrait

Maurizio Fava, MD

Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)

Maria Oquendo, MD, PhD Portrait

Maria Oquendo, MD, PhD

Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania, Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania

Bridget Walton, MS Portrait

Bridget Walton, MS

VP, Global Regulatory Affairs

Kenneth Alper, MD Portrait

Kenneth Alper, MD

Clinical Associate Professor of Psychiatry and Neurology at the New York University School of Medicine

Peter Gasser, MD Portrait

Peter Gasser, MD

Clinical Advisor

Stanley D Glick, MD PhD Portrait

Stanley D Glick, MD PhD

Scientific Advisor

Matthew W Johnson, PhD Portrait

Matthew W Johnson, PhD

Clinical Advisor

Kim PC Kuypers, PhD Portrait

Kim PC Kuypers, PhD

Scientific Collaborator & Advisor

Matthias Liechti, MD, PhD Portrait

Matthias Liechti, MD, PhD

Scientific Collaborator & Advisor

Carol Vallone Portrait

Carol Vallone

Chair of the Board of Directors, Chair of Compensation Committee, Member of Audit/Finance Committee

Natalie Wheeler, PhD Portrait

Natalie Wheeler, PhD

Medical Science Liaison with Dova Pharmaceuticals

John Rotrosen, MD Portrait

John Rotrosen, MD

Professor of Psychiatry with New York University’s Langone’s Department of Psychiatry

Andreas Krebs Portrait

Andreas Krebs

Vice Chair of the Board of Directors, Chair of Nomination and Governance Committee, Member of Audit/Finance Committee

Brigid Makes Portrait

Brigid Makes

Board Director, Chair of Audit/Finance Committee, Member of Compensation Committee, Member of Nomination and Governance Committee

Carrie Liao, CPA Portrait

Carrie Liao, CPA

VP, Corporate Controller & Principal Accounting Officer

Peter Mack, PhD Portrait

Peter Mack, PhD

VP, Pharmaceutical Development

Carole Abel, MBA Portrait

Carole Abel, MBA

VP, Programs and Portfolio Office (PPO)

Here to Stay

We’re built for operational agility and a long-run business model

This is a rapidly evolving space; we’re committed to building a business that becomes a long-lasting institution in effective mental health treatment — not a flash-in-the-pan startup that’s here today and gone tomorrow.

Patients-first

We’re a new kind of pharma company

We believe that, as a society, we’re at the start of a paradigm shift in mental health. We want to lead the way in doing it right. That means we’re community-focused, honest, and transparent. Together we can improve our collective mental health.

Quotation Marks

MindMed could have the key to providing the upsides of psychedelic drugs for both focus and addiction treatment—while cutting out the downsides of tripping.”

MindMed named one of 36 startups that could change the world